Louise Tyvaert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Louise Tyvaert has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Louis Maillard
Departments of Neurology, and University Hospital of Nancy, Lorraine University
3 shared publications- Antoine Verger
CHRU Nancy, Department of Nuclear Medicine, Nancyclotep Imaging Platform, Nancy, France
2 shared publications Jean-Pierre Vignal
Departments of Neurology, and University Hospital of Nancy, Lorraine University, France
2 shared publications- Laurent Koessler
IMoPA (UMR7365), Université de Lorraine, CNRS , Nancy F-54000
2 shared publications - Louis Maillard
Video‐Electroencephalographic Monitoring Unit, Department of Neurology Central Hospital, Nancy Regional University Hospital Center Nancy France
2 shared publications - William Szurhaj
Clinical Neurophysiology Department, Amiens University Medical Center, France; UR 7516, CHIMERE, Jules Verne University of Picardie, Amiens, France
2 shared publications
Latest Publications
- 8 April 2025
- Published by Elsevier in Revue Neurologique
- Vol. 181 (5) , 445-449
Are antiseizure medications disease modifiers?
- 8 April 2025
- Published by Elsevier in Revue Neurologique
- Vol. 181 (5) , 445-449
Are antiseizure medications disease modifiers?
- Open Access
Brain 18 F ‐fluorodeoxyglucose positron emission tomography: An efficient tool at the initial diagnosis of nonlesional late onset epilepsy
Objective: This study evaluates the diagnostic performance and prognostic value of brain 18 F‐fluorodeoxyglucose ( 18 F‐FDG) positron emission tomography (PET) at the initial diagnosis of patients with nonlesional late onset epilepsy (NLLOE). Methods: In this cohort study at the University Hospital of Nancy, France, newly diagnosed NLLOE patients, >50 years old, were consecutively included from June 2017 to January 2021 and systematically underwent brain 18 F‐FDG PET. They were categorized into four presumed etiological NLLOE subtypes: neurodegenerative subtype (NDS; patients with a diagnosis of neurodegenerative disease), microvascular subtype (MVS; patients with ≥3 cardiovascular risk factors and ≥2 vascular lesions on magnetic resonance imaging), inflammatory subtype (IFS; patients meeting international criteria for encephalitis), and unlabeled subtype (ULS). A systematic patient follow‐up (at least 2 years) allowed assessment of cognitive outcomes under antiseizure medication by comparing for each patient the proportion of preserved/altered scores between initial and second neuropsychological assessment. Brain 18 F‐FDG PET was analyzed using a combined visual and semiquantitative approach at the individual level. Results: Eighty‐seven patients were included (NDS, n = 18; MVS, n = 22; IFS, n = 7; ULS, n = 40). A normal 18 F‐FDG PET was observed in 46% of patients, with the final diagnosis of 88% of these patients excluding a neurodegenerative or inflammatory disorder. 18 F‐FDG PET had a negative predictive value of 94% for a cognitive decline at follow‐up, similar for the overall population ( n = 71) and the ULS population ( n = 32). Moreover, a PET hypometabolic pattern suggestive of a neurodegenerative disorder was indicative of cognitive decline at follow‐up in 74% of cases. Significance: 18 F‐FDG PET as part of the initial diagnosis of NLLOE patients may have a significant impact on both NLLOE diagnosis and cognitive prognosis. For almost half of NLLOE patients, a normal 18 F‐FDG PET could help to exclude neurodegenerative and inflammatory epilepsy etiologies as well as future cognitive decline.
Open AccessBrain 18 F ‐fluorodeoxyglucose positron emission tomography: An efficient tool at the initial diagnosis of nonlesional late onset epilepsy
Objective: This study evaluates the diagnostic performance and prognostic value of brain 18 F‐fluorodeoxyglucose ( 18 F‐FDG) positron emission tomography (PET) at the initial diagnosis of patients with nonlesional late onset epilepsy (NLLOE). Methods: In this cohort study at the University Hospital of Nancy, France, newly diagnosed NLLOE patients, >50 years old, were consecutively included from June 2017 to January 2021 and systematically underwent brain 18 F‐FDG PET. They were categorized into four presumed etiological NLLOE subtypes: neurodegenerative subtype (NDS; patients with a diagnosis of neurodegenerative disease), microvascular subtype (MVS; patients with ≥3 cardiovascular risk factors and ≥2 vascular lesions on magnetic resonance imaging), inflammatory subtype (IFS; patients meeting international criteria for encephalitis), and unlabeled subtype (ULS). A systematic patient follow‐up (at least 2 years) allowed assessment of cognitive outcomes under antiseizure medication by comparing for each patient the proportion of preserved/altered scores between initial and second neuropsychological assessment. Brain 18 F‐FDG PET was analyzed using a combined visual and semiquantitative approach at the individual level. Results: Eighty‐seven patients were included (NDS, n = 18; MVS, n = 22; IFS, n = 7; ULS, n = 40). A normal 18 F‐FDG PET was observed in 46% of patients, with the final diagnosis of 88% of these patients excluding a neurodegenerative or inflammatory disorder. 18 F‐FDG PET had a negative predictive value of 94% for a cognitive decline at follow‐up, similar for the overall population ( n = 71) and the ULS population ( n = 32). Moreover, a PET hypometabolic pattern suggestive of a neurodegenerative disorder was indicative of cognitive decline at follow‐up in 74% of cases. Significance: 18 F‐FDG PET as part of the initial diagnosis of NLLOE patients may have a significant impact on both NLLOE diagnosis and cognitive prognosis. For almost half of NLLOE patients, a normal 18 F‐FDG PET could help to exclude neurodegenerative and inflammatory epilepsy etiologies as well as future cognitive decline.
- 23 September 2023
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (12) , 1713-1715
Therapeutic drug monitoring as an essential tool to ensure clozapine efficacy and prevent its toxicity in smokers: a case report
- 23 September 2023
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (12) , 1713-1715
Therapeutic drug monitoring as an essential tool to ensure clozapine efficacy and prevent its toxicity in smokers: a case report
- 19 August 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 111, 151-157
How valid are proxy assessment of mental health and sleep comorbidities of patients with epilepsy using standardized questionnaires?
- 19 August 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 111, 151-157
How valid are proxy assessment of mental health and sleep comorbidities of patients with epilepsy using standardized questionnaires?
- Open Access
- 16 May 2023
- Published by Elsevier in Clinical Neurophysiology
- Vol. 150, e157
N°266 – Intra-cerebral correlates of scalp EEG ictal discharges based on simultaneous recordings
- 16 May 2023
- Published by Elsevier in Clinical Neurophysiology
- Vol. 150, e157
Open AccessN°266 – Intra-cerebral correlates of scalp EEG ictal discharges based on simultaneous recordings
- Open Access
- 15 February 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (1) , 287
Transcranial Direct Current Stimulation Reduces Epileptic Seizure Impact: a video-stereoelectroencephalography case report
- 15 February 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (1) , 287
Open AccessTranscranial Direct Current Stimulation Reduces Epileptic Seizure Impact: a video-stereoelectroencephalography case report
- 15 February 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179 (4) , 316-329
How autoimmunity changed our diagnostic practice in epileptology?
- 15 February 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179 (4) , 316-329
How autoimmunity changed our diagnostic practice in epileptology?
- Open Access
- 24 September 2022
- Published by Elsevier in NeuroImage: Clinical
- Vol. 36, 103210
Metabolic connectivity is associated with seizure outcome in surgically treated temporal lobe epilepsies: A 18F-FDG PET seed correlation analysis
- 24 September 2022
- Published by Elsevier in NeuroImage: Clinical
- Vol. 36, 103210
Open AccessMetabolic connectivity is associated with seizure outcome in surgically treated temporal lobe epilepsies: A 18F-FDG PET seed correlation analysis
- 27 February 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 268 (8) , 3000-3010
Recurrent seizures of autoimmune origin: emerging phenotypes
Objective Recurrent seizures of autoimmune origin (AEp) are one of the most frequent causes of recurrent seizures or suspected epilepsy of unknown cause. The aim of this study was to identify specific phenotypes corresponding to AEp. Methods We retrospectively reviewed features of patients with recurrent seizures of unknown cause and investigated for suspected AEp (January 2015–May 2018). Patients were separated in: (1) AEpAb+: AEp with positive autoantibodies; (2) AEpAb−: suspected AEp (inflammatory central nervous system (CNS) profile) without autoantibodies; (3) NAEp: epilepsy without CNS inflammation. Results Eighty-nine epileptic patients underwent a CSF antibody detection. From the remaining 57 epileptic patients (32 excluded for a differential diagnosis), 61.4% were considered as AEp. 21% were AEpAb+ (4 NMDAR, 2 GABAbR, 3 GAD-Ab, 2 LGi1, 1 CASPR2), 40.4% AEpAb−, and 38.6% NAE. AE (AEpAb+ and AEpAb−) was significantly associated with antibody prevalence in epilepsy (APE) score ≥ 4 (80%), encephalitic phase (71.4%), psychiatric involvement (64.7%), cognitive impairment (50%), and status epilepticus (41.2%). Within the group of 29 patients without encephalitic phase and with chronic epilepsy (NEPp), 34.5% were defined as AEp. 10.4% were AEpAb+ (2 GAD, 1 CASPR2) and 24.1% were AEpAb−. NEP AEp was associated with non-cerebral autoimmune disorders, short epileptic disease duration, and cognitive impairment. Conclusions Autoimmune cause (AEp) should be assessed in patient suffering from recurrent seizures of unknown cause. Acute encephalitis is clearly the main AEp phenotype. AEp was also defined in more than one-third of chronic epilepsy patients (NEP) of unknown cause. Then, AEp may be combined with other autoimmune comorbidities, a shorter evolution of recurrent seizures, and cognitive impairment.
- 27 February 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 268 (8) , 3000-3010
Recurrent seizures of autoimmune origin: emerging phenotypes
Objective Recurrent seizures of autoimmune origin (AEp) are one of the most frequent causes of recurrent seizures or suspected epilepsy of unknown cause. The aim of this study was to identify specific phenotypes corresponding to AEp. Methods We retrospectively reviewed features of patients with recurrent seizures of unknown cause and investigated for suspected AEp (January 2015–May 2018). Patients were separated in: (1) AEpAb+: AEp with positive autoantibodies; (2) AEpAb−: suspected AEp (inflammatory central nervous system (CNS) profile) without autoantibodies; (3) NAEp: epilepsy without CNS inflammation. Results Eighty-nine epileptic patients underwent a CSF antibody detection. From the remaining 57 epileptic patients (32 excluded for a differential diagnosis), 61.4% were considered as AEp. 21% were AEpAb+ (4 NMDAR, 2 GABAbR, 3 GAD-Ab, 2 LGi1, 1 CASPR2), 40.4% AEpAb−, and 38.6% NAE. AE (AEpAb+ and AEpAb−) was significantly associated with antibody prevalence in epilepsy (APE) score ≥ 4 (80%), encephalitic phase (71.4%), psychiatric involvement (64.7%), cognitive impairment (50%), and status epilepticus (41.2%). Within the group of 29 patients without encephalitic phase and with chronic epilepsy (NEPp), 34.5% were defined as AEp. 10.4% were AEpAb+ (2 GAD, 1 CASPR2) and 24.1% were AEpAb−. NEP AEp was associated with non-cerebral autoimmune disorders, short epileptic disease duration, and cognitive impairment. Conclusions Autoimmune cause (AEp) should be assessed in patient suffering from recurrent seizures of unknown cause. Acute encephalitis is clearly the main AEp phenotype. AEp was also defined in more than one-third of chronic epilepsy patients (NEP) of unknown cause. Then, AEp may be combined with other autoimmune comorbidities, a shorter evolution of recurrent seizures, and cognitive impairment.
- 1 April 2020
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 50 (2) , 87-92
Short-term risk of relapse after a first unprovoked seizure in an adult population
- 1 April 2020
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 50 (2) , 87-92
Short-term risk of relapse after a first unprovoked seizure in an adult population